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Retinoblastoma 1 (Rb1) is an essential gene regulating cellular proliferation, differentiation,
and homeostasis. To exert these functions, Rb1 is recruited and physically interacts with
a growing variety of signaling pathways. While Rb1 does not appear to be ubiquitously
expressed, its expression has been conﬁrmed in a variety of hematopoietic and neuronal-
derived cells, including the inner ear hair cells (HCs). Studies in transgenic mice
demonstrate that complete germline or conditional Rb1 deletion leads to abnormal cell
proliferation, followed by massive apoptosis; making it difﬁcult to fully address Rb1’s
biochemical activities.To overcome these limitations, we developed a tetracycline-inducible
TetO-CB-myc6-Rb1 (CBRb) mouse model to achieve transient and inducible dominant-
negative (DN) inhibition of the endogenous RB1 protein. Our strategy involved fusing
the Rb1 gene to the lysosomal protease pre-procathepsin B (CB), thus allowing for
further routing of the DN-CBRb fusion protein and its interacting complexes for proteolytic
degradation. Moreover, reversibility of the system is achieved upon suppression of
doxycycline (Dox) administration. Preliminary characterization of DN-CBRb mice bred to
a ubiquitous rtTA mouse line demonstrated a signiﬁcant inhibition of the endogenous
RB1 protein in the inner ear and in a number of other organs where RB1 is expressed.
Examination of the postnatal (P) DN-CBRb mice inner ear at P10 and P28 showed the
presence of supernumerary inner HCs (IHCs) in the lower turns of the cochleae, which
corresponds to the described expression domain of the endogenous Rb1 gene. Selective
and reversible suppression of gene expression is both an experimental tool for deﬁning
function and a potential means to medical therapy. Given the limitations associated with
Rb1-null mice lethality, this model provides a valuable resource for understanding RB1
activity, relative contribution to HC regeneration and its potential therapeutic application.
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INTRODUCTION
Retinoblastoma 1 is the founding member of the pocket pro-
teins family, which also includes p107/Rbl1 and p130/Rbl2 genes
(Cobrinik, 2005). Rb1 has well-established roles in a wide variety
of tissues for the regulation of cell proliferation, differentiation,
and apoptosis through interactions with a growing number of
molecules, including the E2F family of transcription factors that
regulates the cell cycle (Korenjak and Brehm, 2005; Sun et al.,
2006). Association of un- or hypophosphorylated “active” RB1
with different members of the E2F family prevents entry into the
S phase of the cell cycle (Korenjak and Brehm, 2005; Sun et al.,
2006). During the G1 phase of a normal cell cycle, RB1 is pro-
gressively phosphorylated by the complex formed by cyclin D1
and members of the cyclin D-dependent kinases (CDKs; Adams,
2001). Phosphorylated RB1 becomes “inactive,” releasing its asso-
ciated E2F transcription factor, thereby allowing for transition
into the S phase (Korenjak and Brehm, 2005; Sun et al., 2006). For
more than two decades, it has been known that inactivation of the
Rb1 pathway is a common feature in virtually all human tumors
(Sherr, 1996; Classon and Harlow, 2002; Sherr and McCormick,
2002). Such noteworthy ﬁndings suggest that it is nearly impossi-
ble for a human cell to undergo proliferation without inactivating
Rb1 (Sherr, 1996). Nevertheless, most of the mechanisms under-
lying Rb1 activity in quiescent and proliferating cells remain to be
addressed.
Consistent with RB1’s nodal role in multiple pathways, exper-
imental attempts to conventionally delete RB1 in transgenic mice
have led to abnormalities in the hematopoietic and nervous system
(Lee et al., 1992), as well as in bones (Thomas et al., 2001), kidneys
(Zhu et al., 2009), teeth (Andreeva et al., 2012), skin (Wang et al.,
2014), the digestive tract (Guo et al., 2009), cochlea (Mantela et al.,
2005; Weber et al., 2008), and retina (Knudson, 1971; Lohmann
and Gallie, 2004), followed by massive cell death and embry-
onic lethality at midgestation (Lee et al., 1992; Wu et al., 2003).
While conditional Rb1 deletion through the Cre-Lox recombi-
nation system helps overcome problems with early embryonic
lethality, it still leads to massive cell death, as expected from the
permanent deletion of such a key cell survival and homeostasis
regulator (Chau andWang, 2003; Mantela et al., 2005;Weber et al.,
2008).
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During the past decade, there has been a growing interest
in exploring the potential therapeutic application of Rb1 inac-
tivation in tissue regeneration (Bakay et al., 2006; Goodrich,
2006; Du and Searle, 2009; Knudsen and Wang, 2010; Wang
et al., 2013) and, in particular, in HC regeneration (Man-
tela et al., 2005; Sage et al., 2005, 2006; Weber et al., 2008).
Nevertheless, to this date there are no models available that
would allow for reversible inactivation of Rb1 and its associ-
ated factors. Such studies would be greatly facilitated by using
mice harboring Rb1 conditional null alleles. We report here
the generation and characterization of the TetO-DN-CB-myc6-
Rb1 (DN-CBRb) mouse model, which combines the inducible
nature of the tetracycline-controlled transcriptional activation
(TetO) system, the lysosomal fusion protease pre-procathepsin
B (CB), and part of the Rb1 coding sequence to generate a
dominant-negative (DN) mutant RB1. As with any other pro-
tein destined to the lysosome, CB is synthesized by endoplasmic
reticulum (ER)-bound ribosomes, post-translationally modiﬁed
in the Golgi, and eventually routed to the lysosome (Komi-
nami et al., 1991; Li et al., 1996). On the other hand, RB1
physically interacts with and modulates the activity of many
different cellular proteins (Morris and Dyson, 2001; Goodrich,
2006). Hence, the combination of the fusion protease CB with
the Rb1 gene results in a transgene that can exert a DN effect
upon the endogenous RB1 protein, as well as any other protein
that associates with RB1 (Li et al., 1996, 2000). DN mutations
are most easily described in proteins that function as dimers or
multimers. To date, there is no evidence of RB1 homodimer-
ization. Nonetheless, the inherent nature of its activity allows
for the presence of multiple molecules associated with RB1 at
any given time (Goodrich, 2006). Whenever the RB1-interacting
complex has more than one RB1 binding site, which is occu-
pied by a DN-CBRb protein, it will elicit DN inhibition of the
endogenous RB1 protein and result on an RB1-null phenotype.
Moreover, if at least one RB1 molecule in the RB1 interact-
ing complex is a DN-CBRb, it will prevent the entire complex
from fulﬁlling its normal role, diverting it to the lysosome for
degradation.
We describe here the generation of a DN RB1 transgene and
provide evidence of its functionality in vitro and in vivo. Breed-
ing of this mouse to tissue-speciﬁc promoters driving either tTA
or rtTA lines, in the absence or presence of doxycycline (Dox),
respectively, will result in the expression of the DN-CBRb fusion
protein, which can bind to RB1-interacting molecules, promoting
its lysosomal degradation. Initial characterization of the DN-
CBRb mouse model supports DN inhibition of the RB1 protein
in a number of different systems where Rb1 expression is known,
including the inner ear. Consistent with RB1’s expression proﬁle in
the postnatal (P) organ of Corti (OC; Mantela et al., 2005), super-
numerary inner HCs (IHCs) were observed along the length of
the cochlea at P10 and P28, particularly concentrated in the mid-
dle and basal turns of the cochlea. The intrinsic property of the
CB fusion protein, associated with RB1-mediated protein–protein
interaction and combined with the reversible inducibility of the
TetO system, makes this an interesting mouse model to assess the




The DN-CBRb transgenic developed in this study is viable
and exhibits no developmental abnormalities. Genomic DNA
from wild-type and DN-CBRb positive (DN-CBRb+) mice were
submitted to standard PCR as described below. PCR prod-
ucts from both genotypes were puriﬁed and sequenced using
an ABI Prism® 3100 genetic analyzer to conﬁrm the muta-
tion site. The rtTA (B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae/J:
Jaxmice stock number 006965) mouse line was purchased from
the Jackson Laboratories. Double positive mice carrying both the
DN-CBRb transgene and rtTA inducer allele (DN-CBRb+/ROSA-
CAG-rtTA+) were used for experiments. Experimental negative
control groups consisted of mice negative for CBRb and posi-
tive for rtTA (DN-CBRb−/ROSA-CAG-rtTA+), as well as mice
positive for CBRb and negative for rtTA (DN-CBRb+/ROSA-
CAG-rtTA−). Generation of the DN-CBRb transgenic line and
all animal care and experiments associated with this study were
approved by the Creighton University Institutional Animal Care
and Use Committee (IACUC).
GENERATION OF CB-Myc6-Rb1 TRANSGENIC CONSTRUCT
To test the possibility of using fusion with a lysosomal protease as
an effective means of causing DN inhibition of RB1, we ampliﬁed
a 1583bp-long Rb1 cDNA fragment corresponding to the amino
acid region 369–896 of the RB1 protein (528 amino acids). This
fragment was cloned between the EcoR1 and XbaI restriction sites
of the pCS2+CB-Myc6 vector (a gift from Dr. Marshal Horwitz,
University of Washington; Li et al., 1996, 2000), to fuse it with the
1012bp long CB-Myc6 construct (337 amino acids; Figure 1A).
The fusion product resulted in a peptide of 865 amino acids with
CB- Myc6 at the N-terminus and Rb1 at the C-terminus. The
fusion product has an approximate size of 108 kDa, which is
slightly smaller than the endogenous RB1 protein (∼110 kDa).
The CB-Myc6-RB fusion fragment was PCR ampliﬁed and cloned
into a pTet-splice vector between the SalI and EcoRV restriction
sites to obtain the Tet(O)-DN-CBRB under tetracycline promoter
(Figure 1B).
IN VITRO TESTING OF THE DN-CBRb TRANSGENE AND GENERATION OF
THE TRANSGENIC MOUSE
To stimulate in vitro overexpression and test the reversibility of
the transgene, puriﬁed pTet-Splice plasmid containing the DN-
CBRb cassette was co-transfected into HEK293 cells, with both
DN-CBRb and the tetracycline-controlled transactivator pCMV-
Tet3G vector (Clonetech Laboratories, Inc.), for 24 h. After that
period, Dox media was removed and a subset of cells were washed
from two to three timeswith PBS and incubated inDox-freemedia
for an additional 24 h to allow for inactivation of the transgene.
Control samples consisted of co-transfected cells not treated with
Dox, as well as HEK293 cells transfected only with the transacti-
vator pCMV-Tet3G vector and treated with Dox for a 24-h period.
Upon conﬁrmation of effective Dox regulation of the DN-CBRb
transgene, the entire cassette from the promoter up to the end of
the SV40 polyA terminator element was excised out of the vector,
gel puriﬁed, and used for the generation of the transgenic founder
mice. The foundermice were generated using standard techniques
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FIGURE 1 | Generation of the CB-Myc6-Rb1 construct. (A) cloning of the
Rb1 fragment into the pCS2-CB-Myc6 vector. A 1583bp Rb1 gene product
was PCR ampliﬁed using Forward and Reverse primers. The resulting Rb1
fragment was cloned between EcoRI and Xbal restriction sites of pCS2
vector containing CB-Myc6 construct (a 1012bp CB gene fragment and a
hexameric Myc6 sequence tag), as described previously (Li et al., 1996,
2000). (B)The CB-Myc6-Rb1 fragment was cloned into the pTetSplice
vector between the SalI and EcoRV restriction sites.
at the Mouse Genome Engineering Core facility, University of
Nebraska Medical Center. Pups were genotyped using a primer
set speciﬁc to the CB-Rb1 fusion region, consisting of forward
primer 5′ CTGTGGCATTGAATCAGAAATTGTGGCTGG 3′ and
reverse primer 5′ GTACTTCTGCTATATGTGGCCATTACAACC
3′ (Figure 1B), which ampliﬁed a product approximately 401 bp
(60 bp CB region + 341 Rb1 region; Figure 2). Several indepen-
dent DN-CBRb founder lines were identiﬁed. Five of these lines
were conﬁrmed for germline transmission of the transgene. Two
FIGURE 2 | Genotyping of the DN-CBRb mouse model. PCR with
primers speciﬁc for the CB-Rb1 fusion transgene resulted in a 401 bp band
in the DN-CBRb-positive animals (lanes 2, 4, and 5), but not in those lacking
the transgene (lanes 1 and 3). rtTA genotype was carried following the
protocol available at the Jackson Laboratories website (http://jaxmice.jax.
org/strain/006965.html). (+) = Control DNA showing the transgene.
(−) = Control PCR not containing DNA. M = 100 bp DNA ladder.
of those lines were further bred to establish breeding colonies and
to test the transgene expression (i.e., lines 7 and 14). However, the
results herein presented correspond to data collected from line 14
only. Reproductive problems with line 7 have precluded us from
fully analyzing that line.
TRANSFECTION OF THE DN-CBRb TRANSGENE IN HEI-OC1 CELLS
HEI-OC1 cells, kindly provided by Dr. Fedrico Kalinec (David
Geffen School of Medicine, UCLA, Los Angeles, CA, USA), were
maintained at 33◦C with 10% CO2 (at permissive conditions)
with 10% DMEM (#11965-084, GIBCO-BRL). 10,000 cells were
plated on a 96-well plate and allowed to incubate overnight.
On the following day transient transfection of DN-CBRB and
rtTA construct was done using lipid based transfection reagent
DharmaFECT Duo (T-2010-03). HEI-OC1 transfection rate was
calculated based with pmR-ZsGreen1 (Clontech), wherein the
transfected cells exhibited green ﬂuorescence. 2 ug of pmR-
ZsGreen1 was transfected in parallel, in a separate well. 1 ug/mL
Dox was provided for experimental samples. Plasmid expres-
sion was measured 24 h after transfection and transfection rate
was calculated by counting the number of GFP positive cells
over the total cells labeled with Hoechst. A transfection rate of
∼70% was estimated. Of note, the treatment of untransfected
HEI-OC1 cells with Dox did not affect RB1 protein expression
or cell proliferation. Cell proliferation was assessed by CyQuant
NF cell proliferation kit (Invitrogen, C35007). Cell proliferation
assay was performed 48 h after transfection, according to manu-
facturer’s protocol. Brieﬂy, the cell culture media was removed
and 100 μl of 1X dye binding solution was added into each
microplate well. The microplate was incubated for additional 1 h
at 37◦C. The ﬂuorescence intensity for each sample was measured
using ﬂuorescence microplate reader (FLUOstar OPTIMA, BMG
Labtech), with excitation at 485 nm and emission detection at
530 nm. To quantify any potential cell death following trans-
fection, HEI-OC1 cells were trypsinized and counted. 0.1 × 106
cells were plated on a coverglass in a 12-well plate and incubated
overnight at 37◦C. On the following day, cells were transfected
with the DN-CBRb and rtTA constructs using DharmaFECT Duo
(T-2010-03), lipid based transfection reagent. Positive control
samples consisted of untransfected HEI-OC1 cells treated with
1 μM Staurosporine for 4 h. After 48 h of incubation, HEI-
OC1 cells were analyzed for detection of active caspases according
to the manfacturer’s protocol (Millipore, APT523). Brieﬂy, 1X
CaspaTag reagent solution was added and the cells were incu-
bated at 37◦C for 1 h. 5 ug/ml DAPI was used to label the
nuclei of the dying cells for 10 min at room temperature. The
cells were washed twice with 1X wash buffer and ﬁxed using
the supplier provided ﬁxative. Thereafter, the coverslips were
mounted and observed under the epiﬂuorescence microscope
(Nikon Eclipse 80i).
IN SITU HYBRIDIZATION (ISH)
Whole-mount ISH detecting DN-CBRb mRNA was performed
on Dox-treated (experimental) and untreated (control) P21
DN-CBRb+/ROSA-CAG-rtTA+ mice cochleae as previously
described (Barritt et al., 2012). An approximately 600 nucleotides
long riboprobe was generated by in vitro transcription of
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PCR products derived from DN-CBRb cDNA using primer
5′GGCTGGCAGCCAACTCTTGGAACCTTGACTGG.Reacted tis-
sues were whole mounted in glycerol to be observed under the
microscope or embedded on OTC media prior to frozen section-
ing on a microtome cryostat. Whole mount and sections were
imagedbydifferential interference contrastmicroscopyon aNikon
Eclipse 80i microscope. Sections of the cochlea and spiral gan-
glion neurons were counterstained with Nuclear Fast Red (Vector
Laboratories, H3403).
RNA EXTRACTION AND QUANTITATIVE RT-PCR ANALYSIS
Total RNA was isolated from dissected cochleae using RNeasy kit
(Qiagen) according to the of the manufacturer’s instructions. Up
to 20 μg of total RNA were treated with RNase-free DNase (Turbo
DNfree; Ambion), and RNA concentration and quality were
assessed on a Nanodrop spectrophotometer and Agilent Bioan-
alyzer, respectively. 250 ng of RNA were reverse transcribed using
MultiScribe reverse transcriptase and random primers (Applied
Biosystems). Semi-quantitative PCR assay was done in tripli-
cate for each sample using SYBR green (Applied Biosystems,
StepOne plus system). A corresponding ampliﬁcation for each
sample was performed with template without reverse transcrip-
tase enzyme and used as control to rule out any possible genomic
contamination. Ampliﬁcation was performed using primers set
speciﬁc to theCB-Rb1 fusion region, consisting of forward primer:
5′ CTGTGGCATTGAATCAGAAATTGTGGCTGG-3′ and reverse
primer 5′TACTTCTGCTATATGTGGCCATTACAACC-3′, for 40
cycles. The relative quantitation of mRNA abundance was nor-
malized to endogenous β-Actin using StepOne Software (Applied
Biosystems; version 2.1). T-tests were performed on the normal-
ized gene expression values to determine whether differences were
statistically signiﬁcant. P < 0.05 was considered signiﬁcant.
REGULATION OF THE DN-CBRb TRANSGENE IN VIVO
To enable transgene expression, the DN-CBRb mice were bred
to the ROSA-CAG-rtTA tetracycline inducer line. Genotyping of
the rtTA construct was performed as described at the Jackson
Laboratories website (http://jaxmice.jax.org/strain/006965.html).
Double-positive (DN-CBRb+/ROSA-CAG-rtTA+) and negative
controls (DN-CBRb−/ROSA-CAG-rtTA+, DN-CBRb+/ROSA-
CAG-rtTA−) mice were treated with 2 mg/ml Dox in drinking
water (post-weaning) or through their lactating mothers (pre-
weaning). Alternative Dox doses have been tested (e.g., lower
or higher than 2 mg/ml). However, as the method relies on
the volume of water consumed by the animals, lower doses
proved to be less efﬁcient, resulting on a high variability on
the phenotype. Such variability was attributed to a decrease on
the volume of water consumed by some animals, and conse-
quently smaller Dox absorption. When higher than 2 mg/ml
was used, animals tended to drink less water (and absorb
less Dox) due to Dox’s bitter taste. Further experiments with
injectable Dox at concentrations higher than 2 mg/mL showed
no differences from what we normally observe when provid-
ing 2 mg/mL Dox in the drinking water. Hence, we proceeded
with Dox in drinking water. At the end of the Dox-treatment,
several tissues were harvested (e.g., cochlea, eye, liver, heart,
lung, and kidney) from DN-CBRb+/ROSA-CAG-rtTA+ and
DN-CBRb+/ROSA-CAG-rtTA− control mice and either stored in
RNAlater® stabilization solution (Ambion) for subsequent RNA
or protein extraction or kept in 4% paraformaldehyde (PFA) for
histological analysis.
WESTERN BLOT
The tissues collected in RNA later and stored at −80◦C were
homogenized in Ripa lysis buffer (Thermo scientiﬁc #89901) with
protease inhibitor (Thermo scientiﬁc #88664). Homogenization
was done using Omni Homogenizers. Lysates obtained from tis-
sues or cells were centrifuged at 14,000 rpm for 20min at 4◦C. The
supernatant was used for protein estimation using the Lowrey
method (BioRad DC protein assay kit #500–0112). Thereafter,
20 μg of protein was resolved on 10% SDS-PAGE and proteins
were then transferred to PVDFmembranes in a Bio-Rad TransBlot
apparatus according to the manufacturer’s instructions at 100 V
for 90 min. The proteins were transferred to PVDF membrane
(Millipore Immobilon-P IPVH304FO) at 100 V for 90 min using
a Biorad wet-tank apparatus. After incubation in blocking solu-
tion, the PVDF membrane was blocked in 5% blocking solution
for 2 h at room temperature and probed overnight at 4◦C with
anti-RB1 (antibody against total RB1 protein; Abcam, ab6075),
anti- active caspase 3 (Millipore, AB3623), anti -c-myc (Sigma,
c3956) and anti β-actin (Santa Cruz, sc-69879) overnight at 4◦C.
The membranes were then washed and incubated in appropriate
HRP-conjugated secondary antibodies, anti-rabbit (Santa Cruz,
sc-2054) and anti-mouse (Santa Cruz, sc-358923) for 1 h at RT.
After washing, peroxidase-bound protein bands were visualized
by chemiluminescence using ECL substrate (Pierce, Rockford, IL,
USA).
HISTOLOGICAL ANALYSIS
Whole mount immunohistochemistry was performed as previ-
ously described (Rocha-Sanchez et al., 2011). Immunohistolog-
ical staining of Myosin VIIa (M7a; Proteus Biosciences) and
active capsase 3 (Millipore, AB3623) was performed on DN-
CBRb+/ROSA-CAG-rtTA+ and DN-CBRb−/ROSA-CAG-rtTA+
formalin-ﬁxed whole-mount preparations of dissected cochlear
neurosensory epithelia. Tissue pieces (apex, middle, and base)
were block/permeabilized with 5% NGS/0.1% Tween 20 at room
temperature for 2–3 h, incubated with a primary antibody for
48 h in blocking buffer, and washed three times with PBS. Samples
were then labeledwithAlexa 568-conjugated secondary antibodies
(1:500; Invitrogen), washed with PBS, counterstained with DAPI
(5 ug/ml) for 2 h at room temperature. The cochleae were then
mounted using Prolong anti-fade (Invitrogen) and imaged using
a Leica TCS SP8 MP confocal microscope. Cell counting was per-
formed on 200X images obtained from three different regions
(apex, middle, and base) of the DN-CBRb+/ROSA-CAG-rtTA+
and DN-CBRb−/ROSA-CAG-rtTA+ (control) cochleae. Statis-
tical analysis between the two groups was done using paired
t-test. Values are represented as ±SEM. P < 0.05 was considered
signiﬁcant.
PHALLOIDIN LABELING
F-actin was stained with Alexa 488 conjugated phalloidin. Brieﬂy,
formalin-ﬁxed cochleae were washed with PBS three times and
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permeabilized with 0.25% Triton X-100 for 10 min. Thereafter,
the cochlear tissue was labeled with Alexa 488-phalloidin (1: 200;
Sigma–Aldrich) for 30min. After three washes with PBS, the spec-
imens were counterstained with DAPI, and imaged using Leica
TCS SP8 MP confocal microscope.
PROLIFERATION ASSAY
To label mitotically active cells, a single, subcutaneous injection of
the thymidine analog 5-ethynyl-2′-deoxyuridine (EdU; 50 mg/kg)
in DMSO was administered to DN-CBRb+/ROSA-CAG-rtTA+
and DN-CBRb+/ROSA-CAG-rtTA− mice 4 h before tissue har-
vesting. EdU incorporation into DNA of whole-mount cochlea
was detected using the Click-iT EdU Alexa 488 Fluor Imaging kit
(Invitrogen) and double stained with DAPI following the man-
ufacturer’s instructions and experimental procedures previously
described (Kaiser et al., 2009; Rocha-Sanchez et al., 2011). Samples
were imaged using a Leica TCS SP8 MP confocal microscope.
RESULTS
GENERATION OF THE TEMPORALLY AND CONDITIONALLY INDUCIBLE
DN-CBRb TRANSGENE
To overcome the inherent problems associated with complete and
permanent Rb1 deletion in mice, we sought to develop a DN ver-
sion of the RB1 protein that would not only inhibit RB1 activity,
regardless of the presence of functional endogenous RB1, but also
bind to and trigger proteasome-mediated degradation of the pro-
tein complexes that normally associate with RB1. To this end, we
modiﬁed a previously published system (Li et al., 1996, 2000) con-
sisting of the fusion of the preprocathepsin B protease associated
with most of the entire pocket domain and C-terminal region of
Rb1. The resultant CB-myc6-RBf1C (DN-CBRb) cassette has a
carboxyl-terminal deletion between residues 369 and 896 (Li et al.,
1996, 2000). To avoid the complications associated with constitu-
tive Rb1 elimination, the DN-CBRb cassette was cloned under
the tetracycline inducer Tet(O) promoter as described inmaterials
and methods (Figures 1A,B). In vitro testing of the construct was
performed inOC derivedHEI-OC1 cells by transient transfection.
Expression of the fusion protein was detected byWestern blot with
anti-RB1 antibody, as described below.
IN VITRO ASSESSMENT OF THE CB-Myc6-Rb1 CONSTRUCT
To test the effectiveness of Dox-regulatedDN-CBRbactivation and
the reversibility of the system, HEK 293 cells were co-transfected
with puriﬁed pTet-Splice plasmid containing the CB-Myc6-Rb1
construct and the pCMV-Tet3G vector. Addition of Dox to the
culturemedia signiﬁcantly inhibited the expression of the endoge-
nous RB1 protein (Figure 3). Following a 24-h period, Dox
treatment was withdrawn and a subset of those Dox-treated HEK
293 cells was provided with a Dox-free media for an additional
24 h. Consistent with the reversible nature of the system, RB1
expression was restored in those cells after Dox removal from the
culture media (Figure 3). Noteworthy, no changes in RB1 expres-
sion were observed on co-transfected HEK 293 cells not treated
with Dox or on Dox-treated HEK 293 cells transfected with the
pCMV-Tet3G vector only (Figure 3).
To investigate whether the inhibition in RB1 expression leads to
increase in cell proliferation, HEI-OC1 cells were co-transfected
FIGURE 3 |TetO-driven, Dox-activated expression of the DN-CBRb
transgene leads to downregulation of the endogenous RB1 in vitro.
HEK293 cells, which endogenously express RB1 (Chano et al., 2006),
were co-transfected with TetO-DN-CB-myc6-Rb1, and the pCMV-Tet3G
transactivator vector. In the absence of Dox, co-transfected HEK293 cells
stably expressed RB1 (lane 1). Addition of Dox to the system for a 24-h
period led to TetO-DN-CB-myc6-Rb1 activation and RB1 downregulation
(lane 2). Culturing a subset of those Dox-treated cells in a Dox-free media
for an additional 24 h allowed for RB1 expression to be resumed (lane 3).
C = Control HEK293 cells transfected with pCMV-Tet3G only, treated
with Dox.
with pTet-Splice-DN-CBRb and pCMV-Tet3G vectors and sub-
mitted or not (control group) to Dox treatment, as described
above. Increase in proliferation was quantiﬁed by measuring the
DNA content in both experimental and control groups, as well
as in untransfected HEI-OC1 cells. Consistent with the activa-
tion of the DN-CBRb construct, the results demonstrated that
co-transfection with pTet-Splice-DN-CBRb and pCMV-Tet3G
vectors, followed byDox-induced gene expression, led to amodest,
but signiﬁcant increase in DNA content compared to the control
groups, which is an indirect measure of increase in cell number
(Figure 4). In contrast, no signiﬁcant changes in DNA content
were observed between transfect HEI-OC1 cells not treated with
Dox and untransfected HEI-OC1 (Figure 4). Next, to assess the
possibility of cell death following activation of the DN-CBRb
construct, the protein levels of active caspase 3 were measured
by immunoblotting. Positive control consisted of HEI-OC1 cells
treated with 1 μM Staurosporine. Overall, no signiﬁcant changes
in active caspase 3 protein levels were observed between untrans-
fected control (treated and untreated with Dox) and experimen-
tal (transfected/Dox-untreated and transfected/Dox-treated) cells
even after 48 h of transfection (Figure 5A). These resultswere reca-
pitulatedby in situ caspase detectiononuntransfected controls and
experimental HEI-OC1 cells (Figures 5B,C). In sharp contrast,
signiﬁcant cell death was observed on the Staurosporine-treated
untransfected HEI-OC1 cells (positive control; Figure 5D).
IN VIVO ASSESSMENT OF THE CB-myc6-Rb1 CONSTRUCT ACTIVATION
To investigate the functionality of the CB-myc6-Rb1 construct
in vivo, the pTet-splice vector containing the DN-CBRb cas-
sette was digested with the NotI enzyme to release the trans-
genic cassette, including the promoter and terminator elements.
Gel-puriﬁed DNA was used to generate the transgenic mice
using standard pronuclear injection techniques. DN-CBRb trans-
genic lines were further bred to the ROSA-CAG-rtTA tetra-
cycline inducer line, which enables ubiquitous expression of
DN-CBRb upon Dox administration. Litters from mating of DN-
CBRb to ROSA-CAG-rtTA mice were genotyped as described
in material and methods. DN-CBRb+/ROSA-CAG-rtTA+ and
DN-CBRb−/ROSA-CAG-rtTA+ were Dox-induced and analyzed
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FIGURE 4 | Dox-mediated DN-CBRb transgene activation increases cell
proliferation. HEI-OC1 cells co-transfected with puriﬁed
pTet-Splice-DN-CBRB and the pCMV-Tet3G vectors were cultured in the
absence (−) or presence (+) of Dox. Cell proliferation was determined 48 h
after transfection using CYQUANT NF Proliferation Assay. Percentage
change in proliferation was calculated using change in ﬂuorescence values
with untransfected cells as control. A modest, but signiﬁcant increase in
cell number was observed on transfected cells following Dox treatment. In
contrast, no signiﬁcant changes were observed between transfected
HEI-OC1 cells not treated with (−Dox) and the untransfected control.
*P < 0.05.
for transgene expression. Ten independent DN-CBRb founder
lines were identiﬁed. Five of these lines were conﬁrmed for
germline transmission of the transgene and used as founders
for further breeding. Currently four of those lines are cryopre-
served. The results presented here correspond to one single line
of DN-CBRb mouse. To examine the in vivo feasibility of the
method, we bred the DN-CBRb line with the tetracycline inducer
ROSA-CAG-rtTA mice. DN-CBRb+/ROSA-CAG-rtTA+ mice did
not exhibit any deﬁcits and were further used for transgene induc-
tion experiments. Furthermore, to test for any potential leaky
expression of the DN-CBRb transgene, we measured RB1 protein
expression in DN-CBRb+/ROSA-CAG-rtTA+ mice in the absence
or presence of Dox. Supporting a tight regulation of the trans-
gene by Dox, a signiﬁcant decrease in RB1 protein expression
was observed in DN-CBRb+/ROSA-CAG-rtTA+ mice fed with
Dox, but not in the untreated DN-CBRb+/ROSA-CAG-rtTA+
mice (Figure 6). Given the evidences of speciﬁc Dox regulation
of DN-CBRb+/ROSA-CAG-rtTA+, added to the fact that no leaky
transgene expression was observed on any other genotype com-
bination, either in the presence or absence of Dox, we chose to
use DN-CBRb−/ROSA-CAG-rtTA+ (western blotting and histol-
ogy) and DN-CBRb+/ROSA-CAG-rtTA− (RT-PCR) as negative
controls.
To determine the length of time needed to activate the
ROSA-CAG-rtTA inducer line and elicit the DN-CBRb activation,
DN-CBRb+/ROSA-CAG-rtTA+ mice and DN-CBRb−/ROSA-
CAG-rtTA+ mice were divided into three different groups and
administered Dox in drinking water for 3 (Group 1), 7 (Group 2),
and 10 (Group 3) consecutive days. Immediately after treatment,
protein was extracted from postnatal (P) day 36 mice cochleae
and analyzed by western blot using mouse anti-RB1 and c-myc
hexameric antibodies (Figures 7A–C). Consistent with an initial
accumulation of RB1 protein, quantiﬁcation of RB1-Dox dose
kinetics revealed a more than 20-fold increase in RB1 protein in
cochleae of double-positivemice compared to the negative control
samples (Figures 7A,D). Such accumulationmay reﬂect the detec-
tion of both DN-CBRb and native RB1 subunits, prior to their
association and lysosomal degradation. This notion was further
supported by the observation thatDN-CBRb+/ROSA-CAG-rtTA+
cochleae from groups 2 and 3 displayed steadily less RB protein
than the control samples (Figures 7B–D). Analyses of liver and
heart biopsies conﬁrmed the pattern of RB1-Dox dose kinetics
described above (data not shown). Of note, no signiﬁcant differ-
ences in RB1 expression were observed in mice treated with Dox
for periods longer than 10 consecutive days (data not shown).
Hence, all treatments in subsequent experiments were performed
on a 10-day Dox treatment.
To investigate the reversibility of the DN-CBRb transgene in
vivo, P10 DN-CBRb+/ROSA-CAG-rtTA+ mice were fed with Dox
in drinking water for 10 consecutive days. Controls consisted of
untreatedDN-CBRb+/ROSA-CAG-rtTA+ mice (Group 1;−Dox).
Following that period, animals were euthanized either immedi-
ately (Group 2; +Dox) or 5 days after Dox withdraw (Group 3;
±Dox). Cochleae were dissected and analyzed for RB1 expres-
sion (Figure 8). Compared to the control untreated group, RB1
expression was visibly downregulated on group 1 (Figure 8). On
another hand, supporting the reversibility of the system, RB1
expression on group 3 was increased compared to group 2. These
results are in agreement with previously shown in vitro analysis
(Figure 3).
To assess any potential tissue-speciﬁc variation on the efﬁciency
of the Dox-mediated DN-CBRb activation, DN-CBRb+/ROSA-
CAG-rtTA+ and age-matched DN-CBRb+/ROSA-CAG-rtTA−
mice were treated with Dox for 10 consecutive days. Cochleae,
lungs, heart, and eye biopsies were dissected from experi-
mental and control groups at P18 and subjected to western
blotting with antibody against RB1 (Figure 9A). As expected,
an inter-tissue variation on RB1 expression levels was observed
in the DN-CBRb+/ROSA-CAG-rtTA− group, with retina and
cochleae showing higher RB1 concentrations (Figure 9A). Con-
sistent with the notion of a possible interaction between the
wild-type RB1 and the DN-CBRb transgene, endogenous RB1
expression was consistently decreased in every one of the DN-
CBRb+/ROSA-CAG-rtTA+ mice tissues analyzed (Figure 8A).
In spite of some inter-individual variations on the resid-
ual amount of RB1 protein after transgene activation, RB1
expression was visibly and signiﬁcantly downregulated com-
pared to the control animals (Figures 8A,B). These results
were in agreement with our quantitative RT-PCR analyses in
eye, heart and cochleae of Dox-treated DN-CBRb+/ROSA-
CAG-rtTA+ and age-matched Dox-treated DN-CBRb+/ROSA-
CAG-rtTA− mice, which showed signiﬁcant upregulation of
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FIGURE 5 | Dox-mediated DN-CBRb transgene activation has no effect
on active caspase 3 activation. HEI-OCI cells co-transfected with
TetO-DN-CB-myc6-Rb1 and the pCMV-Tet3G transactivator vector were
cultured in the absence (−) or presence (+) of Dox. (A) Protein
expression of active caspase 3 in the absence or presence of Dox for
24 and 48 h. (B–D) Immunohistochemical analysis of apoptotic cell
death by CaspaTag assay. (B) Untransfected cells. (C) Transfected cells
treated with Dox. (D) Untransfected cells treated with Staurosporine
(positive control). Arrows point to apoptotic cells. S = Untransfected
cells treated with Staurosporine for 4 h ; U = Untransfected cells;
1 = Transfected cells treated with Dox only for 48 h; 2 = Transfected
cells not treated with Dox for 24 h; 3 = Transfected cells treated with
Dox for 24 h; 4 = Transfected cells not treated with Dox for 48 h;
5 = Transfected cells treated with Dox for 48 h. Bar = 10 μm.
FIGURE 6 | Dox-mediated DN-CBRb activation is tightly regulated by
Dox administration. Cochleae of Dox treated (lanes 1–3) and untreated
(lanes 4–6) P10 DN-CBRb+/ROSA-CAG-rtTA+ mice were submitted to
Western blot analysis with anti-RB1 antibody. Consistent with a tight
regulation of the DN-CBRb expression by Dox administration, no
endogenous RB1 expression was observed on DN-CBRb+/ROSA-
CAG-rtTA+ mice cochleae in the presence of Dox.
the DN-CBRb transcript in DN-CBRb+/ROSA-CAG-rtTA+ tis-
sues, but not in DN-CBRb+/ROSA-CAG-rtTA− (Figure 9C).
Moreover, RT-PCR analyses not only conﬁrmed the inducibil-
ity of the system, by showing no transgene upregulation in the
DN-CBRb+/ROSA-CAG-rtTA− mice, but also demonstrated an
increased concentration of the transgene in CBRb+/ROSA-CAG-
rtTA+ animals.
EndogenousRb1 expression is subjected to temporal and spatial
variations (Hamel et al., 1993; Moore et al., 1996; Mantela et al.,
2005). The present results collected from four different tissues
from P18 mice combined with our previous set of experiments
(Figures 7A–D) on P36 mice cochleae, support both the temporal
and spatial efﬁciency of the DN-CBRb transgene activation, as
well as the utilization of the DN-CBRb mouse model in a variety
of studies looking into manipulating RB1 at different postnatal
time points.
DN-CBRb EXPRESSION IN THE MOUSE COCHLEA
To investigate cell-speciﬁc expression of the DN-CBRb transgene,
Dox-treated and untreated (control) P21 DN-CBRb+/ROSA-
CAG-rtTA+ mice cochleae were submitted to ISH with transgene-
speciﬁc riboprobes. Supporting efﬁcient activation and tight regu-
lation of the transgene, strong cytoplasmic and nuclear signal was
detected at the IHCs region, including inner pillar cells and bor-
der cells, throughout the length of the cochlea (Figures 10A–E).
Likewise, hybridization signal was observed on supernumer-
ary cells along the length of the cochlea (Figures 10B,C–E),
suggesting efﬁcient transmission of the transgene to the daugh-
ter cells. No hybridization signal was observed on the control
samples (data not shown). Light hybridization signal was also
observed in the cytoplasma of outer HCs, Deiters’ cells, outer
pillar cells, and spiral ganglion neurons (Figures 10D,F). Cyto-
plasmic detection of the transgene further evidences efﬁcient
transport of the DN-CBRb mRNA from the cells’ nuclei to be
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FIGURE 7 | DN-CBRb transgene activation in the inner ear of
postnatal (P) 36 DN-CBRb+/ROSA-CAG-rtTA+ (CBRb+) and
DN-CBRb−/ROSA-CAG-rtTA+ (CBRb−) mice after 3 (group 1), 7 (group
2), and 10 (group 3) days of Dox treatment. (A–C) Anti-RB1, which reacts
with both hyperphosphorylated and hypophosphorylated forms of RB1, as
well as anti-c-myc antibodies were used for detection. Densitometric
analysis was done using ImageJ software (http://imagej.nih.gov/ij/). The
corresponding values obtained were normalized to the negative control
CBRb (−) and then to β-actin. The relative RB1 expression levels are shown
underneath each blot. (D) Graphic representation of normalized RB1
expression levels plotted against the different treatments highlights a
consistently lower RB1 detection in CBRb+ samples. Each lane on the
Western blot gel (A–C) and each column on the graphic (D) correspond to a
different individual and sample. (−) = CBRb−; *P < 0.05.
translated into active proteins. Noteworthy, mosaic transgene
expression, which is part of the intrinsic nature of trans-
genic constructs, was also observed on DN-CBRb expression
(Figures 10A–F). Such phenomenon is likely the result of incom-
plete recombination, a common occurrence associated with
transgenic constructs. Therefore, incomplete recombination asso-
ciated with the inherent mosaic expression of rtTA inducible
systems may explain, at least in part, the patchy pattern of
supernumerary cells observed on DN-CBRb+/ROSA-CAG-rtTA+
mouse.
FIGURE 8 | Reversible in vivo DN-CBRb transgene regulation. P10
DN-CBRb+/ROSA-CAG-rtTA+ mice were fed with Dox in drinking water for
10 consecutive days. Untreated animals of the same genotype were used
as control group (Group 1; −Dox). At the end of Dox treatment animals
were euthanized either immediately (Group 2; +Dox) or 5 days after Dox
withdraw (Group 3; ±Dox). Supporting the reversibility of the system, RB1
levels were visibly decreased on group 2. Nevertheless, cochleae collected
5 days after Dox withdraw showed RB1 levels, which were comparable to
those of the control group.
TEMPORARY Rb1 DOWNREGULATION IN THE
DN-CBRb+/ROSA-CAG-rtTA+ MOUSE RESULTS IN SUPERNUMERARY
INNER HAIR CELLS
To better understand the possible consequences of temporally
regulated RB1 inhibition in the inner ear, cochleae of DN-
CBRb+/ROSA-CAG-rtTA+ and DN-CBRb−/ROSA-CAG-rtTA+
mice at P10 and P28 were dissected and submitted to immuno-
histochemistry with antibody against the HC marker Myosin VIIa
(M7a). To date, a total of 40 ears (ﬁve mice per genotype × 2 time
points) have been analyzed.While no changes have been observed
in the cochleae of DN-CBRb−/ROSA-CAG-rtTA+ mice, supernu-
merary M7a-positive cells were observed at the IHCs’ region of
DN-CBRb+/ROSA-CAG-rtTA+ cochleae at the two time points
analyzed (Figures 11A–K). Counting of those supernumerary cells
was performed and the results compared between the different
turns of the cochlea (i.e., apex, middle, and base) and time points
by t-test (Figure 11L). No statistical differences were observed
on the concentration of supernumerary cells between the middle
and basal turns at either time points. Nevertheless, comparison
between the numbers of supernumerary cells within the combined
middle and basal turns and the apical turn was found to be signif-
icant (p < 0.05). Likewise, DN-CBRb+/ROSA-CAG-rtTA+ mouse
at P10 showed signiﬁcantly more supernumerary cells (p < 0.05)
than at P28. These results are in agreementwith the expressionpat-
tern of the endogenous Rb1 gene in the mouse cochlea (Mantela
et al., 2005), showing a base-to-apex expression gradient, which
is downregulated during postnatal development. Of note, no sig-
niﬁcant changes were observed in OHCs. Next, to start gathering
information on the morphology of those supernumerary cells, we
looked for the presence and morphology of stereocilia by using
phalloidin labeling on DN-CBRb+/ROSA-CAG-rtTA+ cochlea at
P10. As whole, no visible differences were observed on stereocilia
morphology, density, and orientation between supernumerary
and regular IHCs at P10 (Figures 12A–C). Additional analyses
are currently underway to assess functionality and maturation of
those newly generated HCs.
Unscheduled proliferation of inner ear cells upon complete
or conditional RB1 deletion generally leads to massive cell death
(Mantela et al., 2005; Sage et al., 2005, 2006). In the absence
of any detectable apoptotic-like features in Dox-treated DN-
CBRb+/ROSA-CAG-rtTA+ cochlea, we performed immunohis-
tochemical analysis using antibody speciﬁc to detect any potential
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FIGURE 9 | Spatial analyses of the DN-CBRb transgene activation in
P18 DN-CBRb+/ROSA-CAG-rtTA+ and DN-CBRb+/ROSA-CAG-rtTA−
mice heart, eye, lungs, and cochlea. (A) Conﬁrming efﬁciency of
Dox-mediated transgene activation, expression of the endogenous RB1
was downregulated in the CBRb+/ROSA-CAG-rtTA+ (+) tissues, but not in
the CBRb−/ROSA-CAG-rtTA+ (−) control mice tissues. Densitometric
analysis was performed as described in Figure 4. The relative RB1
expression levels are shown underneath each blot. (B) Graphic
representation of normalized RB1 expression levels plotted against the
different tissues. Inter-individual variation on endogenous RB1 levels may
explain differences in individual responses to transgene activation and RB1
downregulation. (C) RT-PCR analyses in eye, heart and cochleae revealed
signiﬁcant upregulation of the DN-CBRb transcript in dox-treated
DN-CBRb+/ROSA-CAG-rtTA+ tissues, but not in DN-CBRb+/ROSA-
CAG-rtTA−. CBRb+/rtTA+ = DN-CBRb+/ROSA-CAG-rtTA+; CBRb−/
rtTA+ = DN-CBRb−/ROSA-CAG-rtTA+; CBRb+/rtTA− = DN-CBRb+/
ROSA-CAG-rtTA−. *P < 0.05.
active caspase 3 activity in those mice cochleae at P10. Cochleae
treatedwith Staurosporinewere used as a positive control. No pos-
itive caspase 3 labeling was observed, except for a single positive
FIGURE 10 | DN-CBRb transgene expression in a P21
DN-CBRb+/ROSA-CAG-rtTA+ mouse cochlea. (A–F) Strong cytoplasmic
and nuclear ISH signal was observed at the inner hair cells (IHCs), region of
Dox-treated DN-CBRb+/ROSA-CAG-rtTA+ mouse cochlea. (A–D)Transgene
expression was detected throughout the length of the cochlea, but visibly
stronger at the middle and basal regions compared to the apex of the
cochlea. Mosaic DN-CBRb expression was observed (arrows) and may
indicate incomplete recombination in those cells. Likewise, supernumerary
cells (asterisk) showed strong hybridization signal, suggesting efﬁcient
transgene transmission to the newly formed cells. (E) Sections of the
cochlea counterstained with Nuclear Fast Red, conﬁrmed our observations
on whole mount preparations and allowed for a better appreciation of a
supernumerary IHC (asterisk), as well as some light transgene expression
in the spiral ganglion neurons (F). SGN , spiral ganglion neurons;
Bar = 10 μm.
nucleus at the basal turn of one of the ten cochleae analyzed (data
not shown). Likewise, EdU labeling of DN-CBRb+/ROSA-CAG-
rtTA+ cochlea did not reveal any detectable signs of proliferation
within theOC (Figure 12D). However EdU-positive cells were still
observed in the greater epithelial ridge (Figure 12D), suggesting
that proliferation of the cells giving rise to the supernumeraryHCs
took place earlier during the 10 days of Dox treatments. Additional
analyses of DN-CBRb+/ROSA-CAG-rtTA+ mice cochleae submit-
ted to shorter periods of Dox treatment is likely to shed light on
the timing when proliferation is taking place. No EdU-positive
cells were observed in the control DN-CBRb−/ROSA-CAG-rtTA+
mice ears (data not shown).
DISCUSSION
While the use of Rb1 knockout (KO) mice has highlighted Rb1’s
potential role in HC regeneration, early embryonic lethality of
Rb1 KO mice poses serious limitations to undertaking any further
regeneration studies in vivo, particularly in the late embryonic
and postnatal stages (Lee et al., 1992; Wu et al., 2003; Mantela
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FIGURE 11 | Immunohistochemical detection of myosinVIIa (M7a)-
positive supernumerary cells in the cochleae of DN-CBRb+/ROSA-
CAG-rtTA+ (CBRb) at postnatal (P) day 10 and P28. Compared to the
DN-CBRb+/ROSA-CAG-rtTA− (WT) control, which show a single line of cells
at the IHCs’ region throughout the length of the cochlea (A,D,G), P10
(B,E,H–J) and P28 (C,F,K) CBRb mutants exhibited extra M7a-positive cells
(arrows and boxed regions), which were more concentrated in the basal and
middle turns of the cochlea. Of note, the density of supernumerary cells was
higher in P10 ears compared to P28. A close up of boxed areas in (B,E) are
shown in (I) and (J), respectively. Boxed area in (J) highlights an area where
IHCs are seen in as a double row. The blue background in all ﬁgures
corresponds to DAPI staining. Bar = 10 μm. (L) Counting of Myosin
VIIa-positive cells at the IHCs’ region of CBRb mice cochleae at P10 revealed
a signiﬁcant increase in cells, particularly at the middle and basal turns, when
compared to DN-CBRb−/ROSA-CAG-rtTA+ mice. Error bars show SEM.
*P < 0.05.
et al., 2005; Sage et al., 2005, 2006). Moreover, conditional Rb1
deletion in speciﬁc tissues using the Cre/lox system is not always
straightforward (Weber et al., 2008; Turlo et al., 2010). To circum-
vent the problems associated with such approaches, we sought to
generate a mouse model in which RB1 can be conditionally inac-
tivated by overexpressing a DN mutant RB1 in a spatiotemporal
manner. To abolish the function of endogenous RB1, a number
of options have been proposed (Dick, 2007; Macpherson, 2008).
The best alternative would be the one that results not only in the
inactivation of the endogenous RB1, but also its proteolytic degra-
dation. Such a transgenic construct has been previously described
elsewhere (Higashitsuji et al., 2000; Li et al., 2000). However, while
elegant, it lacked a mechanism to control transgene activation,
response, or tissue speciﬁcity. We have generated an inducible
RB1 DN transgenic mouse model that combines the straightfor-
ward strategy of the Dox-dependent transcriptional system to the
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FIGURE 12 | Immunohistochemical localization of stereocilia and
proliferating cells on DN-CBRb+/ROSA-CAG-rtTA+ mouse cochleae.
(A–C) Phalloidin (green) staining of P10 CBRb+/ROSA-CAG-rtTA+ mouse
cochlea revealed the presence of F-actin-positive stereocilia-like structures
(arrows). Due to the peculiar cochleae anatomy, (B,C) were rotated to
facilitate visualization of the stereocilia. (D) EdU (green) labeling in
DN-CBRb+/ROSA-CAG-rtTA+ (CBRb) at P10 showed no proliferation within
the OC; however, a few EdU-positive cells were observed at the greater
epithelial ridge. Asterisks indicate supernumerary cells. DAPI = Blue;
Myosin VIIa = Red. Bar = 10 μm.
fusion of the lysosomal protease CB with Rb1 to generate a tem-
porally regulated Dox-mediated DN-RB1 mouse model. Unlike
othermethods for designing aDNmutation, the proposedmethod
requires minimal knowledge of the gene’s structure and function
and can be potentially applied to any gene of interest (Li et al.,
2000). Moreover, perhaps the most exciting aspect of this method
is the reversibility of the inducible expression of the transgene, in
vitro and in vivo, after Dox withdrawn.
Rb1 is a classical tumor suppressor gene with a variety of func-
tions, ranging fromDNA replication to mitosis, DNA repair, DNA
damage checkpoint control, cellular senescence, differentiation, to
apoptosis (Korenjak and Brehm, 2005). In addition to canonical
bindingwithE2Fduring theG1phase and regulating proliferation,
RB1 binds to a number of transcription factors via protein–protein
interactions to regulate tissue-speciﬁc functions (Welch andWang,
1993; Dick and Dyson, 2003). To our knowledge, there is no
evidence of direct physical interaction between RB1 molecules.
Nevertheless, we hypothesize that some of the numerous RB1-
binding molecules will have multiple RB1 sites, thus allowing for
the presence of multiple RB1molecules at a given time. Consistent
with our hypothesis, BRCA1 has been shown to have RB1-binding
sites in both theC- andN-terminus (Aprelikova et al., 1999;Yarden
and Brody, 1999). In this light, if one of the RB1 molecules is a
DN mutant, it will prevent RB1-containing complex from fulﬁll-
ing their normal role, decreasing the endogenous RB1 levels and
eliciting an RB1-null phenotype (Kominami et al., 1991). While
the full biochemical mechanisms underlying the DN-CBRb activ-
ity are yet to be unveiled, in vivo and in vitro downregulation of the
endogenous RB1 protein following Dox treatment suggests that,
like the BRCA1 protein, more members of the RB1 interactome
may have multiple RB1-binding sites.
In addition to its well-established importance in development
and cancer research, special attention has been paid to the role of
Rb1 in tissue regeneration (Bakay et al., 2006; Wang et al., 2013),
particularly auditory HC regeneration (Mantela et al., 2005; Sage
et al., 2005, 2006; Weber et al., 2008). During the past 8 years,
using the auditory system as a model, we and others have shown
that manipulation of the Rb1 gene or speciﬁc components of the
Rb1 pathway trigger unscheduled proliferation of the otherwise
mitotically quiescent neurosensory HCs and their clonally related
supporting cells (Mantela et al., 2005; Sage et al., 2005; Weber
et al., 2008; Rocha-Sanchez et al., 2011, 2013). Although a growing
repertoire of molecular techniques has substantially contributed
to our understanding of the multifaceted role of Rb1, no approach
to date has been effective in allowing for the understanding of
RB1 activity without permanently eliminating its activity, which,
given Rb1’s broad spectrum of interactions, generally results in
either impaired viability or morbidity (Lee et al., 1992; Wu et al.,
2003). In regard to tissue regeneration, induced and reversible
temporary inactivation of RB1 and its associating factors may lead
to the expansion of targeted cells without triggering cell death,
because RB1 function will be restored once Dox induction is
withdrawn.
We have generated a mouse model that allows for inducible,
reversible, and temporal control of the RB1 protein inhibition at
various postnatal ages. Initial studies on DN-CBRb mice demon-
strate proof of concept for the inducible and reversible inhibition
of endogenous RB1 expression. In the present study, we have
utilized a generic ROSA-CAG-rtTA tetracycline inducer line to
trigger DN-CBRb expression. In vivo and in vitro analyses sup-
port the effectiveness of this model to induce cell proliferation
at rather moderate levels, compared to the conventional Rb1-
KO mouse model, without trigering apoptosis (Mantela et al.,
2005; Sage et al., 2005, 2006; Weber et al., 2008). Contrasting
with the previously described Rb1 mouse models, residual RB1
protein expression is still observed in the DN-CBRb+/ROSA-
CAG-rtTA+. Such RB1 expression levels seem to be low enough
to release those quiescent cells from their postmitotic arrest,
but not to trigger apoptosis, as assumed from our present
results. At this point of our study, we have no experimen-
tal evidences of apoptotic cell death following Dox-mediated
DN-CBRb activation either in vitro or in vivo. An equally sig-
niﬁcant ﬁnding was the observation of supernumerary M7a cells
in the DN-CBRb+/ROSA-CAG-rtTA+ mouse cochleae at two
different postnatal time points. While the number of supernu-
merary cells was higher at P10 than at P28, it is well established
in the auditory ﬁeld that cell proliferation does not naturally
occur once the cells have exit the cell cycle, which happens
during embryonic development. Hence, even the smaller num-
ber of supernumerary cells at P28 is still a positive ﬁnding.
Moreover, attesting to the speciﬁcity of the transgene activity
and consistent with the Rb1 expression pattern in the post-
natal cochlea (Mantela et al., 2005), transgene expression and
the resultant supernumerary cells seems to follow a base-to-
apex gradient of concentration, which is most noticeable at
the IHCs’ region, where Rb1 expression has been previously
described (Mantela et al., 2005). As a matter of fact, all evi-
dences collected so far, suggest that supernumerary cells in the
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DN-CBRb+/ROSA-CAG-rtTA+ mouse cochleae may have been
originated from proliferation of those cells showing upregulation
of theDN-CBRb transgene, particularly the inner IHCs’associated
supporting cells.
The selective suppression of gene expression is both an exper-
imental tool for deﬁning function and a potential means to
medical therapy. Although our research is focused in the audi-
tory system, in view of the central role played by RB1 in various
disease process and lack of available animal models to mod-
ulate its activity, the DN-CBRb model should be a valuable
resource to researchers across various ﬁelds of study. While the
molecular etiology of the retinoblastoma eye tumor is one of
the simplest among all human cancers (Goodrich, 2006), the
signiﬁcance of RB1 functional complexity and interactions, as
well as its relevance in normal development and malignancies,
is a work in progress. For example, germline mutations in
RB1 predispose an individual to a very limited set of cancers
(Kovesdi et al., 1987; Roarty et al., 1988). In contrast, somatic
mutations in RB1 or in members of its interactome appear
to contribute to malignancy in a wide variety of tissues. This
apparent time-dependency on Rb1 function only widens the
current gap between molecular studies of Rb1-mediated gene
regulation and the resultant phenotypes in vivo. While Rb1 is
inactivated in the majority of the malignancies, some types of
cancers, such as colon cancer, require constitutive RB1 expres-
sion to maintain proliferation and prevent apoptosis (Ali et al.,
1993; Du and Searle, 2009; Collard et al., 2012). In such scenar-
ios, temporary inhibition of the RB1 function can potentially
lead to the killing of cancer cells or an increase in their sen-
sitivity to radio- or chemotherapeutic agents (Knudsen and
Knudsen, 2008; Du and Searle, 2009). On the other hand,
in the auditory system, transiently controlled RB1 downregu-
lation may offer an alternative to drive mitotically quiescent
cells back into the cell cycle as a mean to regenerate lost
sensory HCs.
In summary, we have generated a novel inducible, regulated,
and reversible DN-CBRb mouse model, which is the ﬁrst ani-
mal model to achieving a DN inhibition of RB1 protein. To test
the efﬁciency of the construct and potential of the DN-CBRb
mouse model we bred it to a generic rtTA mouse line. How-
ever, to achieve tissue-speciﬁc RB1 inhibition, the DN-CBRb
mice can be bred to any other inducer line, making it a suitable
model for a variety of different studies in the auditory system and
elsewhere.
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